Literature DB >> 19457932

Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs.

Manju Y Krishnan1, Elizabeth J B Manning, Michael T Collins.   

Abstract

OBJECTIVES: To evaluate the BACTEC(TM) MGIT(TM) 960/MGIT Para TB (MGIT) system for drug susceptibility testing of Mycobacterium avium subsp. paratuberculosis (MAP), a pathogen implicated in some forms of Crohn's disease.
METHODS: MICs of 11 drugs for 10 MAP strains were determined using the MGIT system, the BACTEC(TM)460TB system (BACTEC) and conventional agar dilution methods.
RESULTS: MICs determined by MGIT methods showed 80%-100% agreement (+/-1 log(2) dilution) with those determined by the BACTEC and agar dilution methods for ciprofloxacin, levofloxacin, azithromycin and clofazimine. The MGIT and BACTEC methods showed 70%, 80% and 90% agreement (+/-1 log(2) dilution) for MICs of ethambutol, rifabutin and rifampicin; agreement for all drugs increased to 100% at 2 log(2) dilution differences. For clarithromycin, the MGIT method had greater agreement with the agar dilution method (70% at the same dilution) than the BACTEC method (60% at +/-1 log(2) dilution); agreement increased to 100% at +/-2 log(2) dilutions in both cases. The MGIT and agar dilution methods agreed 60% and 100% for amikacin MICs at +/-1 log(2) dilution and +/-2 log(2) dilutions, respectively. By all methods MICs were higher than achievable serum concentrations for isoniazid and dapsone. There was 100% agreement between all three methods for azithromycin, clarithromycin and ciprofloxacin, and 80% agreement for rifampicin using published MIC thresholds available for M. avium complex strains.
CONCLUSIONS: This study shows that the MGIT system can be used for rapid and reliable drug susceptibility testing of MAP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457932     DOI: 10.1093/jac/dkp184

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  In the search of a cause of Crohn's disease.

Authors:  Govind K Makharia; Urvashi B Singh
Journal:  Indian J Gastroenterol       Date:  2009 Sep-Oct

2.  In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria.

Authors:  Tia Dubuisson; Elena Bogatcheva; Manju Y Krishnan; Michael T Collins; Leo Einck; Carol A Nacy; Venkata M Reddy
Journal:  J Antimicrob Chemother       Date:  2010-10-14       Impact factor: 5.790

3.  Vitamins A & D inhibit the growth of mycobacteria in radiometric culture.

Authors:  Robert J Greenstein; Liya Su; Sheldon T Brown
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

4.  Profound remission in Crohn's disease requiring no further treatment for 3-23 years: a case series.

Authors:  Gaurav Agrawal; Annabel Clancy; Roy Huynh; Thomas Borody
Journal:  Gut Pathog       Date:  2020-04-09       Impact factor: 4.181

5.  Analysis of DNA gyrA Gene Mutation in Clinical and Environmental Ciprofloxacin-Resistant Isolates of Non-Tuberculous Mycobacteria Using Molecular Methods.

Authors:  Bahram Nasr Esfahani; Fatemeh Sadat Zarkesh Esfahani; Nima Bahador; Sharareh Moghim; Tooba Radaei; Hadi Rezaei Yazdi; Hajiyeh Ghasemian Safaei; Hossein Fazeli
Journal:  Jundishapur J Microbiol       Date:  2016-03-11       Impact factor: 0.747

6.  The Association of Mycobacterium avium subsp. paratuberculosis with Inflammatory Bowel Disease.

Authors:  Verlaine J Timms; George Daskalopoulos; Hazel M Mitchell; Brett A Neilan
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

Review 7.  Pathogenesis, Molecular Genetics, and Genomics of Mycobacterium avium subsp. paratuberculosis, the Etiologic Agent of Johne's Disease.

Authors:  Govardhan Rathnaiah; Denise K Zinniel; John P Bannantine; Judith R Stabel; Yrjö T Gröhn; Michael T Collins; Raúl G Barletta
Journal:  Front Vet Sci       Date:  2017-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.